Direct-acting antiviral agents for HCV-associated glomerular disease and the current evidence by Fabrizi, Fabrizio et al.
  
Pathogens 2019, 8, 176; doi:10.3390/pathogens8040176 www.mdpi.com/journal/pathogens 
Review 
Direct-Acting Antiviral Agents for HCV-Associated 
Glomerular Disease and the Current Evidence 
Fabrizio Fabrizi 1,*, Roberta Cerutti 1, Giulia Porata 1, Piergiorgio Messa 1,2  
and Ezequiel Ridruejo 3,4,5 
1 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy; 
roberta.cerutti@policlinico.mi.it (R.C.); Giulia.porata@policlinico.mi.it (G.P.); 
Piergiorgio.messa@policlinico.mi.it (P.M.)  
2 Department of Clinical Sciences and Community Health, via Festa del Perdono 7, University of Milan, 
20122 Milan, Italy 
3 Hepatology Section, Department of Medicine, Centro de Educacion Medica e Investigaciones Clinicas 
Norberto Quirno ‘’CEMIC’’, Ciudad Autonoma de Buenos Aires C1425ASG, Argentina; 
eridruejo@gmail.com  
4 Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar,  
Provincia de Buenos Aires B1629AHJ, Argentina 
5 Latin American Liver Research, Educational and Awareness Network (LALREAN), Pilar,  
Provincia de Buenos Aires B1629AHJ, Argentina 
* Correspondence: fabrizio.fabrizi@policlinico.mi.it; Tel.: +39-2-55034552, Fax: +39-2-55034550 
Received: 16 August 2019; Accepted: 28 September 2019; Published: 4 October 2019 
Abstract: Glomerular disease is an extra-hepatic manifestation of hepatitis C virus infection (HCV) 
and membranoproliferative glomerulonephritis is the most frequent glomerular disease associated 
with HCV. It occurs commonly in patients with HCV-related mixed cryoglobulinemia syndrome. 
Patients with HCV-related glomerular disease have been historically a difficult-to-treat group. The 
therapeutic armamentarium for HCV-related glomerular disease now includes antiviral regimens, 
selective or non-specific immunosuppressive drugs, immunomodulators, and symptomatic agents. 
The treatment of HCV-associated glomerular disease is dependent on the clinical presentation of 
the patient. The recent introduction of all-oral, interferon (IFN)-free/ribavirin (RBV)-free regimens 
is dramatically changing the course of HCV in the general population, and some regimens have 
been approved for HCV even in patients with advanced chronic kidney disease. According to a 
systematic review of the medical literature, the evidence concerning the efficacy/safety of direct-
acting antiviral agents (DAAs) of HCV-induced glomerular disease is limited. The frequency of 
sustained virological response was 92.5% (62/67). Full or partial clinical remission was 
demonstrated in many patients (n = 46, 68.5%) after DAAs. There were no reports of deterioration 
of kidney function in patients on DAAs. Many patients (n = 29, 43%) underwent 
immunosuppression while on DAAs. A few cases of new onset or relapsing glomerular disease in 
patients with HCV successfully treated with DAAs have been observed. In summary, DAA-based 
combinations are making easier the management of HCV. However, patients with HCV-induced 
glomerular disease are still a difficult-to-treat group even at the time of DAAs. 
Keywords: direct-acting antiviral agents; glomerulonephritis; hepatitis C virus; mixed 
cryoglobulinemia; proteinuria; sustained virological response 
 
1. Introduction 
More than 71 million people have chronic hepatitis C virus (HCV) infection worldwide. HCV is 
a major health problem, and long lasting HCV results in chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma. HCV plays both a hepatotropic and lymphotropic activity and is an 
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important antigenic stimulus for clonal B cell expansion. The detection of circulating cryoglobulins 
is frequent in patients with chronic HCV (up to 50%) but only 2–3% develop vasculitic symptoms 
that characterize HCV-mixed cryoglobulinemia syndrome. HCV infection is the main cause of mixed 
cryoglobulinemia, a systemic vasculitis producing various clinical manifestations which range from 
the so-called MCS (purpura, asthenia, and arthralgias) to important abnormalities including 
neurological and renal diseases [1,2]. Rheumatoid factor is consistently elevated in 45–68% of cases, 
and low complement titers occur in 51–76% of patients. HCV-MCS is more frequent in women than 
men and affects patients with cirrhosis more commonly than chronic hepatitis. It appears that HCV-
MCS is not affected by HCV genotype, viral load, or duration of HCV infection [1,2]. 
Mixed cryoglobulinemia (MC) represents 60–75% of all cryoglobulinemia and is found in 
connective tissue disease and infectious or lymphoproliferative disorders (i.e., secondary MC) [3]. 
After the identification of HCV, it was recognized as the cause of 80–90% of MC. HCV is usually 
associated with type II MC (which commonly involves an IgM k molecule showing rheumatoid factor 
activity with anti-idiopathic function), although HCV is also associated with type III MC. Around 5–
10% of all MCS have no clear etiology. Cryoglobulinemic vasculitis is classified as essential or 
idiopathic [3]. 
The incidence of HCV-associated glomerular disease is low and this makes it difficult to conduct 
clinical trials to control the disease [3]. Renal disease is now considered an important cause of 
morbidity and mortality in MC vasculitis induced by HCV [3]. Treatment of HCV has made 
considerable progress with the recent introduction of IFN-free combinations of DAAs which 
increased dramatically the rates of viral clearance [3]. The purpose of this review is to report the most 
important data concerning the treatment of HCV-related glomerular disease, an important extra-
hepatic complication of HCV infection. 
2. HCV-Associated Kidney Disease: Histology 
Although HCV has been identified as a prominent agent of tubulointerstitial damage in a large 
series [4], glomerular diseases remain the most frequent kidney disease associated with HCV. The 
relationship between HCV and glomerular disease has been noted in both the native kidneys and 
after solid organ transplant (kidneys, liver, or liver/kidney transplant). In the past two decades, a 
consistent link has been noted between HCV and immune complex (IC) glomerular disease, 
including membranoproliferative and membranous glomerulonephritis [1,2]. 
The most common glomerular disease in HCV-positive patients is cryoglobulinemic 
membranoproliferative glomerulonephritis (MPGN). Other immune complex glomerular diseases 
associated with HCV are non-cryoglobulinemic GN, membranous nephropathy, IgA nephropathy, 
immunotactoid glomerulopathy/fibrillary glomerulonephritis (Table 1). Focal segmental 
glomerulosclerosis and mesangial proliferative glomerulonephritis are additional forms of 
glomerular disease observed in HCV-infected patients. Polyarteritis nodosa is another uncommon 
form of kidney disease associated with HCV. It is probably related to the IC deposition in medium-
sized muscular arteries leading to ischemic changes in the glomeruli. 
Table 1. Kidney disease associated with HCV: pathogenesis and clinical presentation. 
Kidney Disease Pathogenesis Clinical Presentation 
Cryoglobulinemic 
membranoproliferative GNs 
Subendothelial and mesangial cryoglobulin 
deposits; 
mesangial deposits of immune complexes 
(HCV viral antigens, Ig and complement) 
Nephritic or nephrotic 
syndrome 
Noncryoglobulinemic 
membranoproliferative GN 
Mesangial deposits of immune complexes 
(HCV viral antigens, Ig and complement) 
Nephritic or nephrotic 
syndrome 
Mesangial proliferative GN Direct activity of HCV on mesangium  
Proteinuria and/or 
haematuria 
Membranous nephropathy Subepithelial deposits of immune complexes Nephrotic syndrome 
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Berger’s disease (IgA 
nephropathy) 
Mesangial deposits of immune complexes 
Nephritic syndrome, 
isolated proteinuria 
and/or haematuria 
Tubulo-interstitial nephritis 
HCV deposition in tubular epithelial 
(perinuclear areas) and infiltrating cells 
Proteinuria 
Focal and segmental 
glomerulosclerosis 
Direct injury by HCV on podocytes of 
epithelial cells 
Nephrotic syndrome, 
isolated proteinuria 
Polyarteritis nodosa 
Immune complexes in medium-sized 
muscular arteries 
Haematuria and/or 
proteinuria 
Immunotactoid 
glomerulopathy 
Deposits (glomerular capillary wall and 
mesangium) containing microtubular 
structures 
Nephrotic syndrome, 
isolated proteinuria 
and/or haematuria 
Fibrillary GN 
Mesangial deposits (containing randomly 
oriented fibrillar material) (fibrils composed 
of antigen-antibody immune complexes) 
Nephrotic syndrome, 
isolated proteinuria 
and/or haematuria 
We recommend kidney biopsy in HCV-infected patients with clinical evidence of glomerular 
disease. The course of these HCV-associated nephropathies is characterized by remission and 
exacerbation phases. However, the long-term outcome remains poorly defined. 
3. HCV and Kidney-Updated Evidence 
HCV plays several activities in numerous organs and systems other than the liver, including 
kidneys. The kidneys are an important target of the extra-hepatic activity of HCV which causes 
kidney damage in multiple ways. (1) HCV is a cause of tubulointerstitial nephritis [2], even if this 
finding needs to be confirmed in further studies (2). HCV leads to glomerular injury particularly in 
patients with HCV-associated MCS. HCV is an important cause of MCS, a vasculitis involving small 
to medium vessels (3). Finally, HCV supports the development (or the progression) of chronic kidney 
disease in the general population, probably by vascular damage at kidney level [5]. 
A role of chronic HCV infection in the pathogenesis of CKD has been suggested by several 
studies mostly performed in the last decade. The relationship between HCV and CKD is complex and 
shows bidirectional nature. Patients on maintenance dialysis remain at risk for HCV infection due to 
nosocomial transmission of HCV and have a high prevalence of HCV infection. On the other hand, a 
significant frequency of HCV infection has been noted in patients with renal insufficiency at pre-
dialysis stage suggesting a role of HCV in developing CKD [3]. 
A good number of large databases have addressed the relationship between HCV and chronic 
kidney disease. According to a recent systematic review and meta-analysis, aggregating results of 
longitudinal studies (n = 15 studies, n = 2,299,134 unique patients) demonstrated a correlation 
between positive anti-HCV serologic status and increased frequency of CKD, the weighted estimate 
for adjusted HR with HCV across the surveys, 1.54 (95% CI, 1.26; 1.87, p < 0.001). Between-study 
heterogeneity was found (Q-value by chi-squared test, 500.3, p < 0.0001) and this hampered more 
definitive conclusions [5]. An accelerated endothelial damage at kidney level (renal arteries and 
arterioles) has been cited to explain the detrimental role of HCV on the incidence and progression of 
CKD in the adult general population all over the world. Endothelial dysfunction in HCV-infected 
patients is in turn supported by oxidative stress, pro-inflammatory cytokines, peripheral or hepatic 
insulin resistance, or non-alcoholic steatohepatitis (NASH) [5]. 
HCV and CKD are remarkable public health problems worldwide. The overall mean prevalence 
of CKD in the general population is around 13.4% (stages 1 to 5) and 10.6% (stages 3 to 5). Traditional 
risk factors for developing chronic renal disease (diabetes mellitus, arterial hypertension, smoking, 
weight overload) do not explain completely the current prevalence of chronic kidney disease in the 
adult general population of industrialized world. Chronic infections by hepatotropic viruses 
(hepatitis B and hepatitis C viruses) or human immunodeficiency virus (HIV) are non-traditional, but 
modifiable causes of chronic kidney disease [6,7]. The adverse impact of chronic HCV on chronic 
Pathogens 2019, 8, 176 4 of 12 
 
kidney disease suggests the antiviral therapy of all HCV-infected patients, regardless of their stage 
of liver and kidney injury [3]. 
4. Treatment of HCV-Related Glomerular Disease: Historical Perspective 
The identification of HCV and a better comprehension of the pathophysiological mechanisms of 
diseases have provided the possibility to treat HCV-associated glomerular disease with various 
approaches. (1) Antiviral therapy has been given with the idea that the underlying infection promotes 
the synthesis of immune complexes and resultant glomerular disease; (2) Nonspecific 
immunosuppressive agents (corticosteroids, cyclophosphamide, azathioprine, etc.) lowering 
glomerular inflammation have been adopted by several authors; (3) An additional choice is given by 
rituximab (RTX), which selectively targets B cells and causes depletion of B cells. Thus, RTX 
diminishes the synthesis of IgM with rheumatoid factor (RF) activity that bind HCV-IgG immune-
complexes; (4) RBV mono-therapy proved to be effective and safe in the treatment of HCV-induced 
glomerular disease post liver transplant due to its immunomodulatory properties [3]; and (5) 
Symptomatic drugs such as diuretics, anti-hypertensive, or antiproteinuric (ACEIs or ARBs) drugs 
should be considered. 
Unlike HBV and HIV, HCV infection can be completely and permanently treated by antiviral 
medications as HCV shows no long-term reservoir in the body. The development of sustained 
virological response (SVR), which is defined as the removal of HCV RNA from serum for 12 weeks 
after antiviral therapy ended, is the definitive cure of HCV infection. Johnson et al. were the first 
authors to report a cohort of patients with HCV-associated glomerular disease who received antiviral 
therapy (mono-therapy with conventional IFN for two to 12 months). Four patients achieved 
reduction of serum HCV RNA and contemporary reduction of proteinuria [8]. 
In the report of Rossi et al., three patients with HCV-associated cryoglobulinemic 
glomerulonephritis received IFN-based therapy (pegylated IFN and RBV) for 12 months. The patients 
underwent percutaneous kidney biopsy at baseline and repeated kidney biopsies 14–26 months after 
antiviral treatment ended. They found lowered glomerular inflammation, and renal vasculitic lesions 
occurred in one patient only at baseline and disappeared after treatment. Subendothelial deposits 
disappeared in two of three patients and the number of mesangial cells and monocytes was reduced 
in all [9]. 
Subsequent studies were performed mostly in patients with HCV-associated cryoglobulinemic 
vasculitis (many with kidney involvement) [1,10]. All the authors observed that the elimination of 
HCV RNA from serum after antiviral therapy gave improvement of clinical abnormalities (including 
renal disease). These reports gave emphasis to the fact that IFN-based therapies are less effective and 
more toxic in individuals with HCV-associated MCS in comparison with the general population 
infected with HCV. 
A systematic review and meta-analysis concerning mono-therapy with conventional or 
pegylated IFN for HCV-MCS in the non-transplant setting was undertaken (n = 11 clinical studies, n 
= 235 unique patients). It showed that the weighted estimate of frequency of sustained virological 
response was 15% (95% CI, 8–22%). The frequency of patients who interrupted antiviral therapy was 
3.4% (most patients experienced minor adverse events which did not require discontinuation of 
therapy). An excellent relationship between virological and clinical response was found (weighted K 
= 0.72). Cirrhosis (p < 0.04), kidney involvement (p < 0.07), and arthralgias (p < 0.04) at baseline showed 
negative impact on viral response [11]. 
The efficacy and safety of combined antiviral therapy (pegylated IFN plus RBV) for the 
treatment of HCV-MCS in non-immunosuppressed population were also evaluated. 10 clinical 
studies (n = 300 unique patients) were retrieved. The frequency of kidney involvement at baseline 
ranged between 4% and 39%. The overall estimate of the frequency of SVR was 42% (95% CI, 31–
54%). The pooled estimate of frequency of patients interrupting (or dose reducing) antiviral therapy 
was 15% (95% CI, 8–21%). A good correlation between viral and clinical response (weighted K = 0.63) 
by a meta-analysis at individual level on a subgroup of studies (n = 3, n = 74 unique patients) was 
noted [12]. 
Pathogens 2019, 8, 176 5 of 12 
 
5. Antiviral Treatment of HCV with DAAs and Renal Impairment 
Direct-acting antiviral agents are molecules that affect the non-structural proteins of HCV and 
block HCV replication. Three groups of DAAs are now available for the treatment of HCV. These 
include NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors [Figure 1]. The 
first-generation NS3/4A protease inhibitors (telaprevir and boceprevir) have been introduced for the 
treatment of HCV in combination with pegylated IFN and RBV (2011). The triple combined antiviral 
regimens (IFN/RBV/telaprevir or boceprevir) increased treatment success, but were poorly tolerated 
[13]. 
 
Figure 1. HCV RNA genome structure and targets for DAAs. 
The standard of care is now given by IFN-free combinations of DAAs. These regimens are very 
effective with SVR rates around 95%, irrespective of the viral characteristics of HCV. Tolerance to 
DAAs is very good- the frequencies of serious adverse events (AEs) are less than 10% and early 
discontinuation rates less than 5% [3]. 
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases 
Society of America (IDSA) have issued clinical guidelines in order to recommend appropriate 
combinations of DAAs in patients with kidney impairment. These guidelines have been updated 
recently (September 2017) [14]. All patients with eGFR ≥ 30 mL/min/1.73 m2 can be treated with any 
licensed DAA-based regimen. As listed in Table 2, three DAA-based regimens have been 
recommended for patients on maintenance dialysis or those with eGFR < 30 mL/min/1.73 m2. 
Sofosbuvir is the key drug of many DAA-based combinations that are currently available, but is not 
suggested in patients with eGFR < 30 mL/min/1.73 m2 due to the accumulation of its active metabolite 
GS-331007. On the grounds of large surveys, we observed remarkable deterioration of kidney 
function following therapy with sofosbuvir-based regimens [15]. The daily fixed-dose 
elbasvir/grazoprevir regimen is recommended for the treatment of genotype 1 infection in patients 
with severe renal dysfunction. The C-SURFER study showed that the elbasvir/grazoprevir 
combination is effective in patients with HCV genotype 1 infection and CKD stage 4/5 [16]. However, 
elbasvir/grazoprevir shows efficacy in patients with intact kidneys and HCV genotype 1 and 4. Thus, 
it has been extrapolated that elbasvir/grazoprevir is efficacious in patients with CKD stage 4/5 and 
HCV genotype 4. The EXPEDITION-4 trial found that the pangenotypic NS3/NS4A protease inhibitor 
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glecaprevir and the pangenotypic NS5A inhibitor pibrentasvir provide a very high rate of viral 
response in patients with HCV genotype 1, 2, 3, 4, 5, and 6 infection [17]. 
Table 2. Regimens based on DAAs currently available for treatment of HCV in CKD. 
Daclatasvir (60 mg) 
CKD stage 1,2,3  
Elbasvir/Grazoprevir (50 mg/100 mg) 
Glecaprevir/Pibrentasvir (300 mg/120 mg) 
Ledipasvir/Sofosbuvir (90 mg/400 mg) 
Sofosbuvir/Velpatasvir (400 mg/100 mg) 
Simeprevir (150 mg) 
Sofosbuvir (400 mg) 
Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100 mg) 
Ritonavir-boosted Paritaprevir/Ombitasvir/Dasabuvir±Ribavirin 
(PrOD or 3D regimen) (50 mg/75 mg/12.5 mg/250 mg/200 mg) 
CKD stage 4,5  
Elbasvir/Grazoprevir (50 mg/100 mg) 
Glecaprevir/Pibrentasvir (300 mg/120 mg) 
Finally, we suggest that serum creatinine and urinary abnormalities should be monitored with 
accuracy in all patients after antiviral treatment with DAAs. New–onset or relapsing glomerular 
disease has been noted by some authors in patients who achieved SVR with regimens based on DAAs 
[18–20]. Figure 2 shows purpuric manifestations in the lower limbs in a patient with HCV-related 
cryogobulinemic patient who received DAAs. After DAAs, the patient obtained SVR but 
cryoglobulins remain detectable in serum. The patient suffered from frequent and spontaneous 
episodes of purpura over the observation period (i.e., three or four times a year). Purpura 
disappeared spontaneously in most cases. 
 
Figure 2. Purpuric manifestations in the legs after successful therapy with DAAs. 
6. Antiviral Treatment of HCV (DAAs) for HCV-Related Glomerular Disease 
As shown in Table 3, reports regarding DAA-based regimens for HCV-related glomerular 
disease are limited [21–29]. Collectively, the frequency of SVR was 92% (62/67). The rate of complete 
clinical response after DAAs was 32.8% (22/67). A number of patients required immunosuppression 
while on therapy with DAAs (n = 29, 43%). Some patients received immunosuppression after antiviral 
therapy ended [28]. 
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Table 3. Viral and clinical response after antiviral therapy with DAAs in patients with HCV-
associated GN. 
 DAAs SVR12 
Complete 
Clinical 
Response 
Partial 
Clinical 
Response 
Concomitant 
IS 
Gragnani L, et al. 
(2016) (n = 4) 
SOF-based regimen 4(100%) 3(75%) 1(25%) 1(25%) 
Sise M, et al. (2016) 
(n = 7) 
SOF+SIM (n = 6) 
SOF+RBV (n = 1) 
6(86%) 3(43%) 4(57%) 2(29%) 
Saadoun D, et al. 
(2016) (n = 5). 
SOF+RBV 4(80%) 0 4(80%) 2(40%) 
Sollima S, et al. 
(2016) (n = 5) 
SOF+RBV 
SOF+DCV 
SOF+SIM 
3D 
5(100%) 0 1(20%) 0 
Emery J, et al. (2017) 
(n = 10) 
SOF+RBV 
SOF+SIM 
3D±RBV 
SOF+LDV±RBV 
7(70%) 2(20%) 2(20%) 4(40%) 
Saadoun D, et al. 
(2017) (n = 5) 
SOF+DCV 5(100%) 3(60%) 1(20%) NA 
Bonacci M, et al. 
(2018) (n = 9) 
SOF-based regimen±RBV 
3D±RBV 
SIM+DCV 
GZR+EBR 
pegIFN+DAAs 
FDV+DLR 
9(100%) 6(67%) 3(33%) 5(55%) 
Fabrizi F, et al. 
(2018) (n = 13) 
SOF+RBV (n = 6) 
3D+RBV (n = 4) 
SOF+LDV (n = 1) 
SOF+DCV+RBV (n = 2) 
13(100%) 3(23%) 7(54%) 9(69.2%) 
Obrisca B, et al. 
(2019) (n = 9) 
3D 9(100%) 2(23%) 1(10%) 6(67%) 
3D+ribavirin (RBV), ritonavir-boosted paritaprevir/ombitasvir/dasabuvir with or without RBV; EBR, 
elbasvir; FDV, faldaprevir; GRZ, grazoprevir; LDV, ledipasvir; PegIFN, pegylated interferon; SIM, 
simeprevir, SOF, sofosbuvir. 
The evidence shown in Table 3 is incomplete. As an example, the details on kidney disease 
(including kidney biopsy) at baseline and after antiviral therapy ended were frequently lacking, the 
information on type and dose of immunosuppressive therapy before, during and after antiviral 
therapies was not extensively given. The low incidence of HCV-related glomerular disease clearly 
hampers the conduction of RCTs or observational studies with large size. 
In addition to the studies reported above, small patient series (reviewed in [29]) and some case 
reports have been published. At our knowledge, at least 11 patients with HCV-associated glomerular 
disease experienced clinical benefit after completing therapy with DAAs [29–34]. 
It is well known that the removal of HCV RNA from serum is frequently accompanied by clinical 
improvement of glomerular abnormalities. However, the clinical remission was incomplete or 
lacking in many patients (Table 3). HCV-related glomerular disease is not easily controlled by 
antiviral therapies, particularly in the case of proliferative or sclerotic injury. Also, information on 
DAAs efficacy in HCV-associated cryoglobulinemic vasculitis is disappointing due to the inability of 
these drugs to inhibit the immune-mediated process once it has been triggered. In other words, even 
with viral eradication, the course of mixed cryoglobulinemic disease or cryoglobulinemic 
glomerulonephritis is difficult to predict. 
The natural history of HCV-induced mixed cryoglobulinemia is clinically variable. Some 
patients have an indolent course while others develop vasculitic lesions in various organs including 
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kidneys. The exacerbation of extra-renal symptoms is often associated with a flare-up of kidney 
disease, but can occur independently. No link between serum complement or rheumatoid factor 
levels and the course of cryoglobulinemic glomerulonephritis has been noted. However, the clearance 
of HCV RNA from serum gives clinicians the opportunity to adopt immunosuppressive therapies 
with no concern on HCV replication. 
As shown in Table 3, while DAA use is common, a small number of patients have been treated 
with IFN and/or RBV and DAAs. Based on the known side effects of IFN and particularly the 
hematologic side effects of RBV [3], we suggest the adoption of IFN-free/RBV-free antiviral therapies 
for HCV-induced glomerular disease. 
Antiviral therapies will evolve in the near future with the introduction of DAAs provided with 
reduced treatment duration and lower prices; this will be an additional advance in the management 
of HCV-related glomerular disease as these patients frequently receive multiple medications due to 
several comorbidities related to HCV. 
7. Immunosuppressive Agents for Treatment of HCV-Related Glomerular Disease 
As mentioned above, the therapeutic armamentarium for HCV-related glomerular disease 
includes numerous agents in addition to antivirals. Immunosuppression has often been employed in 
the past as first-line therapy in cryoglobulinemic vasculitis (particularly when kidney involvement is 
severe) despite the possibility of an exacerbation of infections. 
Table 4 shows that the management of HCV-related glomerular disease is based on the clinical 
manifestations of glomerular disease. Patients showing a cryoglobulinemic flare or severe glomerular 
damage induced by HCV should be treated first with immunosuppressive agents (with rituximab as 
first-line agent) with or without plasma exchange. Current practice is to treat with 
immunosuppressants until the acute phase of disease is overcome. After that, treatment with DAAs 
is suggested. The initial approach includes immunosuppressive therapy alone or combined therapy 
(immunosuppressive drugs and DAAs), according to the decision of the clinician. 
Table 4. Treatment of HCV-related glomerular disease according to clinical presentation. 
Presentation Treatment  
Non-nephrotic proteinuria DAA-based regimen (Table 1) 
ACEIs and/or ARBs 
Diuretics, anti-hypertensive agents  
Stable and mild kidney dysfunction (GFR > 30 
mL/min/1.72 m2) 
Nephrotic syndrome Rituximab, Plasma-exchange, IV 
steroids, mycophenolate mofetil 
DAA based regimen (Table 1) 
ACEIs and/or ARBs 
Diuretics, anti-hypertensive agents 
Cryoglobulinemic flare 
Rapidly progressive glomerulonephritis 
ACEIs = angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor blockers; DAAs = 
direct-acting antiviral agents; GFR = glomerular filtration rate; iv = intravenous. 
Patients with mild or moderate forms of HCV-induced glomerular disease (stable kidney 
function and/or non-nephrotic proteinuria) should be treated with DAAs. Patients with HCV-
induced glomerular disease who are resistant or intolerant to DAA therapies should be given 
immunosuppressive agents. In all cases, treatment with antiproteinuric agents such as angiotensin-
converting enzyme inhibitors and/or angiotensin-receptor blockers should be considered to achieve 
a maximal antiproteinuric response. Diuretics and anti-hypertensive agents should be given where 
clinically requested. 
8. Rituximab for Treatment of HCV-Related Glomerular Disease 
RTX is currently the first-line immunosuppressive agent for HCV-related glomerulonephritis 
[3]. RTX is a monoclonal antibody directed at the lymphocyte membrane-protein CD20 and it gives 
selective depletion of CD20 positive B lymphocytes. Thus, RTX abolishes IgM production and 
cryoglobulins. Two RCTs have demonstrated the superiority of rituximab mono-therapy as 
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compared with conventional immunosuppressive therapy (i.e., corticosteroids, azathioprine, 
cyclophosphamide, and plasma exchange) for the management of HCV-associated cryoglobulinemic 
vasculitis in individuals for whom prior IFN therapy failed to give disease remission, or in patients 
who were not eligible for IFN therapy [35,36]. Of note, only a minority of these patients suffered from 
kidney involvement. Over 400 patients with mixed cryoglobulinemia have been treated with RTX 
according to a recent and systematic review of the medical literature [37]. 
A long-term (mean follow-up, 72.5 months) prospective, single-centre and open label study has 
been recently published- 31 patients (27 infected with HCV) with symptomatic MC (MC type 2 in 29 
patients and MC type 3 in two patients) received RTX [38]. There were 16 patients with diffuse 
MPGN, 26 patients with peripheral neuropathy, and seven with severe skin ulcers. RTX was given at 
a dose of 375 mg/m2 according to a ‘4 plus 2 protocol’ (four doses at 1, 8, 15 and 22 days, followed by 
two further doses 1 and 2 months later). Five individuals also received intravenous therapy with 
corticosteroids (500 mg/day of methylprednisolone for three consecutive days). No additional 
immunosuppressive medications or antiviral agents were administered. We observed complete 
disappearance of pre-treatment manifestations in all patients with purpuric changes and non-healing 
vasculitic ulcers, and in 80% of peripheral neuropathies. Cryoglobulinemic nephropathy consistently 
improved during the observation period, starting from the second month after RTX (serum creatinine 
from 2.1 ± 1.7 to 1.5 ± 1.6 mg/dL, p < 0.05; and 24-h proteinuria from 2.3 ± 2.1 to 0.9 ± 1.9 g; p < 0.05). 
Improvement of cryoglobulinemic serological hallmarks (including cryocrit and low complement C4) 
were observed and no adverse clinical events were noted [38]. 
We suggest caution about RTX administration as relevant side events have been observed 
following its use for cryoglobulinemic vasculitis. Prospective data from the AIR (Autoimmunity and 
Rituximab) registry, which includes data on patients who received RTX off-label, have reported that 
among patients (n = 23) having non-viral cryoglobulinemia vasculitis on RTX, side effects occurred 
in almost half of the patients (n = 11), including severe infections. Episodes of infection had been 
observed mainly in a subgroup of patients (age >70 years, essential type II MC, GFR < 60 mL/min/1.73 
m2, and simultaneous high dose corticosteroids) and were fatal in some cases (n = 3) [39]. Significant 
kidney impairment at baseline, advanced age and contemporary intravenous high-dose 
corticosteroids were recorded in our patients who had sepsis following RTX administration [40]. One 
single dose of RTX for gastric lymphoma resulted in the occurrence of cholestatic hepatitis in a renal 
transplant (RT) recipient with chronic HCV. An enormous increase of HCV RNA levels after RTX 
administration was noted and the patient died due to bacterial pneumonia [41]. 
9. Non-Selective Immunosuppression for HCV-Related Glomerular Disease 
Plasma exchange has been considered for many years the option of choice for MCS, with or 
without kidney involvement, with the aim of obtaining clearance of circulating cryoglobulins from 
the plasma and lowering the deposition of ICs to the kidneys. Intravenous or oral administration of 
corticosteroids has been given to alleviate inflammation at glomerular level. However, steroids 
support progressive liver disease and replication of HCV [3]. Cyclophosphamide has been selected 
to improve glomerular disease by lowering stimulation of B lymphocytes and cryoglobulin synthesis. 
However, liver toxicity is a serious adverse event that limits its use [42]. Mycophenolate mofetil 
inhibits proliferation of T- and B-lymphocytes, thereby suppressing antibody synthesis and cell-
mediated immune responses. Evidence on mycophenolate mofetil for HCV-associated glomerular 
disease is extremely limited [43]. 
10. Conclusions 
The present review shows that antiviral therapy with DAA combinations provides high rates of 
virological response even in patients with HCV-related glomerular disease. Tolerance was 
satisfactory with no serious adverse events. Viral response is accompanied with some clinical benefit 
and immunosuppressive therapies are required in many cases. Patients with HCV-induced 
glomerular disease are still a difficult-to-treat group even at the time of DAAs. Whether the advent 
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of newer DAAs will reduce the need of immunosuppressive drugs for HCV-related glomerular 
disease is a topic of active research. 
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RF Rheumatoid factor 
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